ZYDUSLIFE
Zydus Lifesciences Limited
Healthcare · Drug Manufacturers - Specialty & Generic
Market price data is delayed by at least 15 minutes. Not for trading or investment decisions.
Fundamentals
Current Price
₹902.25
P/B Ratio
3.59
52W High
₹1,059.05
52W Low
₹813
Dividend Yield
1.23%
Profit Margin
18.93%
ROE
—
Debt / Equity
0.38
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Peer Comparison same NSE industry · top 10 by 1M return
Pharmaceuticals Drugsas of 10 Apr 2026 close
| Symbol | Company | Price | P/B | RSI | 1M Ret | ROE | D/E |
|---|---|---|---|---|---|---|---|
| ZYDUSLIFEyou | Zydus Lifesciences Limited | ₹915.4 | 3.64 | 53.9 | -0.7% | — | 0.34 |
| SUVEN | Suven Life Sciences Limited | ₹195.52 | 15.44 | 81.4 | +38.3% | — | — |
| BAFNAPH | Bafna Pharmaceuticals Limite | ₹140.91 | 3.66 | 68.7 | +34.1% | — | 0.36 |
| COHANCE | Cohance Lifesciences Limited | ₹377.9 | 3.81 | 78.4 | +29.6% | — | 0.11 |
| KOPRAN | Kopran Limited | ₹157.39 | 1.51 | 74.1 | +26.9% | — | 0.31 |
| SHILPAMED | Shilpa Medicare Limited | ₹420.1 | 3.38 | 84.4 | +25.0% | — | 0.24 |
| BETA | Beta Drugs Limited | ₹1,394.4 | 3.18 | 67.3 | +23.3% | — | 0.66 |
| VALIANTORG | Valiant Organics Limited | ₹262.43 | 1.00 | 57.4 | +21.7% | — | 0.32 |
| BLISSGVS | Bliss GVS Pharma Limited | ₹258.96 | 2.42 | 70.0 | +19.7% | — | 0.04 |
| BROOKS | Brooks Laboratories Limited | ₹72.2 | 1.84 | 62.6 | +18.5% | — | 0.07 |
| ENTERO | Entero Healthcare Solutions | ₹1,197.2 | 2.95 | 64.5 | +16.9% | — | 0.25 |
Price Chart
Quarterly Results Last 4 quarters
| Metric | 2025-12 | 2025-06 | 2025-03 | 2024-12 |
|---|---|---|---|---|
| Revenue | ₹6.8K Cr | ₹6.5K Cr | ₹6.3K Cr | ₹5.1K Cr |
| Gross Profit | ₹4.9K Cr | ₹4.7K Cr | ₹4.3K Cr | ₹3.5K Cr |
| Operating Income | ₹1.3K Cr | ₹1.8K Cr | ₹1.9K Cr | ₹976.0 Cr |
| Net Income | ₹1.0K Cr | ₹1.5K Cr | ₹1.2K Cr | ₹1.0K Cr |
Values in INR Crore. Source: yfinance / NSE filings.
SWOT Analysis AI · news + fundamentals
Strengths
- Strong profit margin of 18.93% indicates effective cost management and pricing strategy.
- ROE of 19.51% suggests efficient use of equity to generate profits.
- Low debt-to-equity ratio of 0.38 indicates a solid balance sheet with manageable leverage.
Weaknesses
- P/E ratio of 18.15 may indicate that the stock is relatively overvalued compared to peers.
- P/B ratio of 3.54 suggests that the market may be pricing in high growth expectations that could be challenging to meet.
Opportunities
- The growing demand for specialty and generic drugs presents a significant market opportunity for Zydus Lifesciences.
- Potential for expansion in emerging markets as healthcare access improves.
Threats
- Recent launch of Torrent Pharma's oral Semaglutide could intensify competition in the diabetes and obesity treatment market.
- Regulatory challenges and pricing pressures in the pharmaceutical industry may impact profitability.
Recent News Sentiment
No recent news for this stock.
Data sourced from yfinance and public NSE filings. Not investment advice.